NCT01390311View on ClinicalTrials.gov

Azacitidine After Chemotherapy and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Previously Treated With Donor Stem Cell Transplant

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

March 31, 2014

Study Completion Date

April 30, 2015

Conditions
Leukemia, Myeloid, AcuteMyelodysplastic Syndromes
Interventions
DRUG

Azacitidine

DRUG

Pre-DLI Salvage Chemotherapy

At the discretion of the treating physician

BIOLOGICAL

Donor Leukocyte Infusion (DLI)

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Washington University School of Medicine

OTHER

NCT01390311 - Azacitidine After Chemotherapy and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Previously Treated With Donor Stem Cell Transplant | Biotech Hunter | Biotech Hunter